These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

69 related items for PubMed ID: 1539561

  • 21. C2 monitoring of cyclosporine in stable renal transplant patients results in lower costs and improved renal function.
    Domínguez J, Fuenzalida D, Norambuena R, Pais E, Cortes Monroy G, Llanos R.
    Transplant Proc; 2005 Apr; 37(3):1583-5. PubMed ID: 15866680
    [Abstract] [Full Text] [Related]

  • 22. C2 monitoring in maintenance renal transplant recipients: is it worthwhile?
    Midtvedt K, Fauchald P, Bergan S, Høieggen A, Hallan S, Svarstad E, Bergrem H, Eriksen BO, Pfeffer PF, Dalen I, Leivestad T.
    Transplantation; 2003 Oct 27; 76(8):1236-8. PubMed ID: 14578761
    [Abstract] [Full Text] [Related]

  • 23. An improved glomerular filtration rate in cardiac transplant recipients with once-a-day cyclosporine dosing.
    Bunke M, Sloan R, Brier M, Ganzel B.
    Transplantation; 1995 Feb 27; 59(4):537-40. PubMed ID: 7878758
    [Abstract] [Full Text] [Related]

  • 24. Achieving adequate cyclosporine exposure in liver transplant recipients: a novel strategy for monitoring and dosing using intravenous therapy.
    Lück R, Böger J, Kuse E, Klempnauer J, Nashan B.
    Liver Transpl; 2004 May 27; 10(5):686-91. PubMed ID: 15108262
    [Abstract] [Full Text] [Related]

  • 25. Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study.
    Oberbauer R, Kreis H, Johnson RW, Mota A, Claesson K, Ruiz JC, Wilczek H, Jamieson N, Henriques AC, Paczek L, Chapman J, Burke JT, Rapamune Maintenance Regimen Study Group.
    Transplantation; 2003 Jul 27; 76(2):364-70. PubMed ID: 12883194
    [Abstract] [Full Text] [Related]

  • 26. [Pharmacokinetics and therapeutic monitoring of cyclosporine in liver transplant recipients].
    Cheymol G.
    Bull Acad Natl Med; 1992 Oct 27; 176(7):1023-31; discussion 1031-2. PubMed ID: 1493564
    [Abstract] [Full Text] [Related]

  • 27. Effects of H2-receptor antagonists on renal function in cyclosporine-treated renal transplant patients.
    Pachon J, Lorber MI, Bia MJ.
    Transplantation; 1989 Feb 27; 47(2):254-9. PubMed ID: 2645708
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Phase I safety and pharmacokinetic studies of brequinar sodium after single ascending oral doses in stable renal, hepatic, and cardiac allograft recipients.
    Joshi AS, King SY, Zajac BA, Makowka L, Sher LS, Kahan BD, Menkis AH, Stiller CR, Schaefle B, Kornhauser DM.
    J Clin Pharmacol; 1997 Dec 27; 37(12):1121-8. PubMed ID: 9506007
    [Abstract] [Full Text] [Related]

  • 30. Pharmacokinetics of cyclosporine A after intravenous and oral administration in liver transplant patients measured with high-performance liquid chromatography.
    Klompmaker IJ, Wierda JM, Sluiter WJ, Uges DR, Haagsma EB, Verwer R, Slooff MJ.
    Ther Drug Monit; 1993 Feb 27; 15(1):60-4. PubMed ID: 8451783
    [Abstract] [Full Text] [Related]

  • 31. Measurement of AM19 and other cyclosporine metabolites in the blood of liver transplant patients with stable liver function.
    Liu WT, Levy GA, Wong PY.
    Ther Drug Monit; 1995 Oct 27; 17(5):479-86. PubMed ID: 8585111
    [Abstract] [Full Text] [Related]

  • 32. Cimetidine and omeprazole do not affect cyclosporine disposition by the rat liver.
    Bar-Meir S, Bardan E, Ronen I, Krepel Z, Garti M.
    Eur J Drug Metab Pharmacokinet; 1993 Oct 27; 18(4):355-8. PubMed ID: 8020534
    [Abstract] [Full Text] [Related]

  • 33. Cholestasis and kidney dysfunction in liver transplant patients reduces cyclosporine metabolite excretion.
    Tötterman A, Lalla M, Salmela K, Höckerstedt K.
    Transpl Int; 1992 Oct 27; 5 Suppl 1():S190-2. PubMed ID: 14621772
    [Abstract] [Full Text] [Related]

  • 34. The kinetics of cyclosporine and its metabolites in bone marrow transplant patients.
    Schwinghammer TL, Przepiorka D, Venkataramanan R, Wang CP, Burckart GJ, Rosenfeld CS, Shadduck RK.
    Br J Clin Pharmacol; 1991 Sep 27; 32(3):323-8. PubMed ID: 1777368
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Cimetidine kinetics and dynamics in patients with severe liver disease.
    Villeneuve JP, Fortunet-Fouin H, Arsène D.
    Hepatology; 1983 Sep 27; 3(6):923-7. PubMed ID: 6629322
    [Abstract] [Full Text] [Related]

  • 38. Cyclosporine trough concentration monitoring in liver transplant patients.
    Burckart GJ, Ptachcinski RJ, Venkataramanan R, Iwatsuki S, Esquivel C, Van Thiel DH, Starzl TE.
    Transplant Proc; 1986 Dec 27; 18(6 Suppl 5):188-93. PubMed ID: 3538569
    [Abstract] [Full Text] [Related]

  • 39. Preliminary study of effects of multiple oral dosing of clarithromycin on the pharmacokinetics of cyclosporine in dogs.
    Katayama M, Kawakami Y, Katayama R, Shimamura S, Okamura Y, Uzuka Y.
    J Vet Med Sci; 2014 Mar 27; 76(3):431-3. PubMed ID: 24189617
    [Abstract] [Full Text] [Related]

  • 40. Safety of cimetidine.
    Kruss DM, Littman A.
    Gastroenterology; 1978 Feb 27; 74(2 Pt 2):478-83. PubMed ID: 620916
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 4.